TRM Ltd, P. O. Box 93, York, YO43 3WE, UK.
Curr Pharm Des. 2013;19(31):5486-94. doi: 10.2174/1381612811319310004.
The production of recombinant pharmaceutical proteins in plants is entering a new phase with the recent approval of recombinant glucocerebrosidase produced in carrot cells and the successful production of clinical-grade proteins in diverse plant-based production platforms. In the long journey from concept to product, the field of molecular farming has faced technical and economic hurdles, many reflecting the initially limited productivity of plants compared to established platforms such as mammalian cells. This challenge has been met by innovative research aiming to increase recombinant protein yields and maximize the economic benefits of plants. Research has focused on increasing the intrinsic yield capability of plants by optimizing expression construct design, and also on novel strategies to avoid epigenetic silencing and environmental effects on protein accumulation. In this article, we discuss the diverse approaches that have been used to increase the productivity of plant-based platforms for the production of recombinant pharmaceutical proteins and consider future opportunities to maximize the potential of plants and increase their competitiveness outside niche markets.
植物中重组药物蛋白的生产正在进入一个新阶段，最近批准了在胡萝卜细胞中生产的重组葡萄糖脑苷脂酶，并且在各种基于植物的生产平台上成功生产出临床级别的蛋白。在从概念到产品的漫长旅程中，分子农业领域面临着技术和经济障碍，其中许多反映了与哺乳动物细胞等成熟平台相比，植物最初的生产力有限。通过旨在提高重组蛋白产量和最大化植物经济效益的创新研究，这一挑战得到了应对。研究集中在通过优化表达构建体设计来提高植物的内在产率能力，以及避免表观遗传沉默和环境对蛋白积累影响的新策略。在本文中，我们讨论了为提高植物生产平台生产重组药物蛋白的生产力而采用的各种方法，并考虑了未来最大限度地发挥植物潜力和提高其在利基市场之外竞争力的机会。
